Etonogestrel: 5 agencies, 2009–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “contraception.”, while PBAC (Australia) recorded not recommended for “Contraception”.
The file has been open for more than a decade: 16.8 years separate the first record, 12 Oct 2009 at SMC (Scotland), from the most recent, 2026 at PBAC (Australia).
PBAC (Australia) changed its position: recommended in 2025, not recommended by 2026.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 8 records date from 2023 or later.
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess etonogestrel, on 12 Oct 2009; PHARMAC (New Zealand) did not open a file until 29 Aug 2025 — an unusually long tail of 15.8 years between the earliest and latest system to look at it.
3 of the 5 agencies here assessed etonogestrel more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed etonogestrel.
The full ledger for etonogestrel reads 6 recommended, 1 not recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 17 Dec 2025 | Re-assessment following post-listing study results | SMR substantial · ASMR V | source |
| PHARMAC (New Zealand) | 29 Aug 2025 | Contraception | PTAC advice: Cost Neutral | source |
| PBAC (Australia) | 2025 | Contraception | Recommended | source |
| SMC (Scotland) | 13 Dec 2010 | contraception. | accepted | source |
| AWMSG (Wales) | 16 Aug 2010 | Contraception where safety and efficacy have been established in women between 18 and 40 years of age | outside AWMSG criteria | source |
3 further decisions for etonogestrel, across 3 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 1 further source document.
Related molecules
- levonorgestrel — same ATC class G03A — Sex hormones and modulators
- desogestrel — same ATC class G03A — Sex hormones and modulators
- desogestrel / ethinylestradiol — same ATC class G03A — Sex hormones and modulators
- medroxyprogesterone — same ATC class G03A — Sex hormones and modulators
- drospirenone — same ATC class G03A — Sex hormones and modulators
- cefazolin — also decided by HAS in 2025Q4
Coverage: 8 decisions for etonogestrel from 5 agencies, 2009 to 2026. Data to 7 Sep 2026. ATC class G03A — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.